Treatment of erectile dysfunction (ED); enhancement of penile erection by inhibiting phosphodiesterase type 5 (PDE5), thereby increasing cyclic guanosine monophosphate (cGMP) levels in the corpus cavernosum, promoting smooth muscle relaxation and blood inflow; used as an oral medication for adult males with erectile dysfunction, typically administered at a dose of 50 mg once daily as needed, approximately 1 hour before sexual activity, with a maximum dose of 100 mg per administration; also exhibits potential in preventing or reversing vascular remodeling and enhancing nitric oxide (NO)-mediated vasodilation; investigated for applications in pulmonary vascular diseases due to its PDE5 inhibitory activity.